CAJ | 학술논문

目的：探析异甘草酸镁联合降脂治疗非酒精性脂肪型肝炎疗效及对肝功能影响。方法以该院2011年5月-2014年10月期间所收治92例非酒精性脂肪型肝炎患者展开研究，对照组给予以调脂为主综合治疗，观察组加用异甘草酸镁，比较两组治疗前后PCⅢ、C-ⅠV、HA及ALT、AST、TBIL、γ-GT等肝纤维化指标。结果两组治疗前各肝纤维化指标的比较无统计学意义(P>0.05)；治疗后，观察组PCⅢ、C-ⅠV、HA等指标均显著降低，与治疗前比较差异有统计学意义(P<0.05)，与对照组治疗后的组间比较差异有统计学意义(P<0.05)。组间比较上，两组治疗前ALT、AST、TBIL、γ-GT等肝功能指标的比较无统计学意义(P>0.05)，治疗后两组各指标的比较差异有统计学意义(P<0.05)；组内比较上，两组治疗前后各指标的比较差异有统计学意义(P<0.05)。结论异甘草酸镁可保护肝细胞，与降脂治疗联合应用于NASH患者可有效抑制肝细胞纤维化，促进肝功能的恢复，应用价值高。
목적：탐석이감초산미연합강지치료비주정성지방형간염료효급대간공능영향。방법이해원2011년5월-2014년10월기간소수치92례비주정성지방형간염환자전개연구，대조조급여이조지위주종합치료，관찰조가용이감초산미，비교량조치료전후PCⅢ、C-ⅠV、HA급ALT、AST、TBIL、γ-GT등간섬유화지표。결과량조치료전각간섬유화지표적비교무통계학의의(P>0.05)；치료후，관찰조PCⅢ、C-ⅠV、HA등지표균현저강저，여치료전비교차이유통계학의의(P<0.05)，여대조조치료후적조간비교차이유통계학의의(P<0.05)。조간비교상，량조치료전ALT、AST、TBIL、γ-GT등간공능지표적비교무통계학의의(P>0.05)，치료후량조각지표적비교차이유통계학의의(P<0.05)；조내비교상，량조치료전후각지표적비교차이유통계학의의(P<0.05)。결론이감초산미가보호간세포，여강지치료연합응용우NASH환자가유효억제간세포섬유화，촉진간공능적회복，응용개치고。
Objective To probe into magnesium isoglycyrrhizinate combined with lipid-lowering efficacy in the treatment of non-alcoholic fatty hepatitis and its effect on liver function. Methods 92 patients with cases non-alcoholic fatty hepatitis in our hospital during May 2011-October 2014 were selected as the research object: control group was given lipid based comprehensive treat-ment, which the observation group received comprehensive treatment combined with magnesium isoglycyrrhizinate. PC III, C- I V, HA and ALT, AST, TBIL, -GT and other indexes of hepatic fibrosis gamma of two groups before and after treatment were com-pared. Results Two groups before treatment, difference of indexes of hepatic fibrosis had no statistical significance (P >0.05);af-ter the treatment, the index PC III, C-I V, HA etc of observation group were significantly lower, difference were statistical signifi-cance compared with before treatment (P< 0.05), and control group after treatment between group was statistics significance (P <0.05). Before treatment, differences of liver function index, ALT, AST, TBIL,-GT and other gamma between groups showed no sta-tistical significance (P > 0.05), after the treatment, differences between two groups were statistically significant (P< 0.05); within group comparison, the two groups before and after treatment of each index were statistically significant (P< 0.05). Conclusion Magnesium isoglycyrrhizinate, which can protect the liver cells, combined with lipid-lowering treatment for patients with NASH can effectively inhibit fibrosis of liver cells, promote liver function recovery, so it has high application value.